Commentary. Can Lithium or Valproate Untie Tangles in Alzheimer's Disease?
J Clin Psychiatry 2009;70(6):919-921
© Copyright 2016 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
The article in this issue by Hampel et al1 offers a
glimpse of an interesting chapter in the history of Alzheimer’s disease (AD) treatment research. An understanding
of the significance of this report, which touches
on issues ranging from the identification of novel targets
for treatment to widely differing approaches to trial design,
provides an appreciation of the rapid pace of treatment development
in the field and allows one to gain some insight
into an interesting historical sidebar.
Alzheimer’s disease is now the fourth leading cause of
death in people over age 65 years in the United States and
the only major cause of death that is increasing over time.